What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cancer
CTGF, Internal medicine, Endocrinology, Fibrosis and Cancer research are his primary areas of study.
CTGF is a subfield of Growth factor that he explores.
His studies deal with areas such as Taurine and Vitamin E as well as Internal medicine.
His Endocrinology research includes elements of Downregulation and upregulation and End stage renal disease.
His Fibrosis research entails a greater understanding of Pathology.
His research in Cancer research intersects with topics in Carcinogenesis, Mesangial cell, Signal transduction and Immunology.
His most cited work include:
- Expression of connective tissue growth factor in human renal fibrosis (515 citations)
- Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. (430 citations)
- Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. (382 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Pathology, CTGF, Endocrinology and Fibrosis.
His Pathology study combines topics from a wide range of disciplines, such as Autoantibody, Glomerulonephritis and Immunology.
His CTGF research is multidisciplinary, incorporating perspectives in Diabetic retinopathy, Transforming growth factor, Cancer research and Connective tissue.
The concepts of his Cancer research study are interwoven with issues in Gene silencing and Signal transduction.
His Endocrinology research incorporates themes from Bone morphogenetic protein and Pathogenesis.
The Fibrosis study combines topics in areas such as Inflammation and Matricellular protein.
He most often published in these fields:
- Internal medicine (35.94%)
- Pathology (27.34%)
- CTGF (27.73%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (13.28%)
- Kidney (17.97%)
- Fibrosis (21.48%)
In recent papers he was focusing on the following fields of study:
Roel Goldschmeding mainly focuses on Cancer research, Kidney, Fibrosis, CTGF and Growth factor.
His studies in Cancer research integrate themes in fields like Diabetic nephropathy, Mesangium, Homeostasis, Renal fibrosis and Transforming growth factor beta.
His Kidney research integrates issues from Dyslipidemia, Epidermal growth factor receptor, Kidney disease, Gene silencing and Histology.
Fibrosis is the subject of his research, which falls under Pathology.
His study looks at the relationship between CTGF and topics such as Connective tissue, which overlap with Lymphangiogenesis and Gastroenterology.
In his research, Stem cell, Integrin, Carcinogenesis and DMBA is intimately related to Matricellular protein, which falls under the overarching field of Growth factor.
Between 2017 and 2021, his most popular works were:
- Connective tissue growth factor (CTGF) from basics to clinics (91 citations)
- Cellular senescence in the aging and diseased kidney (57 citations)
- Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype. (35 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cancer
His primary areas of investigation include Cancer research, Kidney, Fibrosis, CTGF and Epidermal growth factor receptor.
His Kidney study incorporates themes from Amphiregulin, Senescence and Kidney disease.
His Fibrosis study integrates concerns from other disciplines, such as Systems biology, Metabolic syndrome, Disease, Gene silencing and SMAD.
The subject of his CTGF research is within the realm of Growth factor.
His biological study spans a wide range of topics, including Regeneration, Angiogenesis, Connective tissue and Cell growth.
His work carried out in the field of Epidermal growth factor receptor brings together such families of science as Epidermal growth factor and Renal fibrosis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
